Table 1

Clinical characteristics of melanoma patients

PatientSexAgeYears since primaryaStagebSite of metastasisPrior therapySpecificity of T-cell response analysed
1BRU 1F5723IIILNcSurgery, vaccinationCMV
2BRU 3F556IVLN, lung, spleenSurgery, vaccinationCMV
3BRU 4M313IIILNSurgery, chemotherapy, vaccinationCMV
4BRU 6M174IVLN, liver, lungSurgery, IFN-α, vaccinationCMV
5GE 3M571IVLN, liver, lungSurgery, vaccinationCMV
6GE 4M550.5IVLN, lung, skinSurgery, vaccinationCMV
7GE 5M550.5IVLN, intestineSurgeryCMV
8LAU 18F733IIILNSurgery, isolated limb perfusionMelan-A
9LAU 50M652IIILNSurgery, chemotherapy, isolated limb perfusionMelan-A
10LAU 56M4110IIILNSurgery, chemotherapy, isolated limb perfusionMelan-A
11LAU 97M595IIILNSurgery, chemotherapy, IFN-αMelan-A, CMV
12LAU 119F735IIILNSurgeryMelan-A
13LAU 132M334IVLN, skinSurgery, IFN-α, vaccinationMelan-A, CMV
14LAU 155M565IVLN, liverSurgery, chemotherapy, IFN-αMelan-A, CMV
15LAU 156M4617IVLN, liver, lungSurgeryMelan-A, CMV
16LAU 169M520.5IVLN, skinSurgery, chemotherapy, IFN-αMelan-A
17LAU 181F410.5IVLNSurgeryMelan-A
18LAU 198F703IIILNSurgery, chemotherapyMelan-A
19LAU 203F675IIILNSurgeryMelan-A, CMV
20LAU 211M800.5IVLN, skinSurgeryMelan-A, CMV
21LAU 212F6910IIILNSurgeryMelan-A
22LAU 233F761IIILNSurgeryMelan-A
23LAU 240M651IIILNSurgeryMelan-A
24LAU 241M491I/IISurgeryCMV
25LAU 253M632IIILNSurgeryMelan-A
26LAU 258F657IIILNSurgeryCMV
27LAU 267M451IIILNSurgery, IFN-αMelan-A
28LAU 269M232IIILNSurgery, isolated limb perfusionMelan-A
29LAU 306M580.5IIILNSurgeryMelan-A
30LAU 321M645IVLN, lungSurgeryMelan-A
31LAU 337F253IVLN, lung, skinSurgery, IFN-α, vaccinationMelan-A
32LAU 343M781IIILNSurgeryMelan-A
33LAU 350M630.5IIILNSurgeryMelan-A
34LAU 352M772IIILNSurgery, vaccinationMelan-A
35LAU 359M611IIILNSurgery, vaccinationMelan-A
36LAU 362F592IVLN, skinSurgeryMelan-A, CMV
37LAU 372M590IIILNSurgeryMelan-A
38LAU 387F593IVLN, skinSurgery, IFN-αCMV
39LAU 390F381IIILNSurgery, chemotherapy, IFN-αCMV
40LAU 392F334IIILNSurgeryMelan-A
41LAU 435M674IIILNSurgeryMelan-A
42LAU 441M641IIILNSurgeryCMV
43LAU 444F313IVLN, skinSurgeryMelan-A
44LAU 450F722IVLN, skin, brainSurgery, vaccinationMelan-A
45LAU 455M5620IVLN, lungSurgery, chemotherapyMelan-A
46LAU 460F617IVLN, skinSurgery, chemotherapy, vaccinationCMV
47LAU 465M486IIILNSurgeryMelan-A
48LAU 498F601IIILNSurgery, vaccinationCMV
49LAU 529M633IVLN, lungSurgery, chemotherapy, vaccinationCMV
50LAU 552F351IVLN, skinSurgery, IFN-αCMV
51LAU 562M555IVLN, skinSurgery, IFN-αCMV
52LAU 567F540.5IIILNSurgery, vaccinationMelan-A, CMV
53LAU 576M570IIILNSurgeryMelan-A
54LAU 608F665IVLN, skinSurgery, isolated limb perfusionCMV
55LAU 622M662IVLN, lung, skinSurgeryMelan-A
56LAU 640F580.5IVLN, skinSurgeryMelan-A
57LAU 651F450.5IVLN, skinSurgeryMelan-A
58LAU 653M563IVLN, skinSurgery, isolated limb perfusionMelan-A
59LAU 671F570IIILNSurgeryCMV
60LAU 709F437IIILNSurgery, vaccinationCMV
61MEL 162M602IIILNSurgery, chemotherapy, IFN-αMelan-A
  • a Years elapsed between excision of primary lesion and sample studied.

  • b American Joint Committee on Cancer staging system.

  • c LN, lymph node; CMV, cytomegalovirus.